Fc␥RIIB are IgG receptors that inhibit immunoreceptor tyrosine-based activation motif (ITAM)-dependent cell activation. Inhibition depends on an immunoreceptor tyrosine-based inhibition motif (ITIM) that is phosphorylated upon Fc␥RIIB coaggregation with ITAMbearing receptors and recruits SH2 domain-containing phosphatases. Agarose bead-coated phosphorylated ITIM peptides (pITIMs) bind in vitro the single-SH2 inositol 5-phosphatases (SHIP1 and SHIP2) and the two-SH2 protein tyrosine phosphatases (SHP-1 and SHP-2). Phosphorylated Fc␥RIIB, however, recruit selectively SHIP1/2 in vivo. We aimed here at explaining this discordance. We found that beads coated with low amounts of pITIM bound in vitro SHIP1, but not SHP-1, i.e. behaved as phosphorylated Fc␥RIIB in vivo. The reason is that SHP-1 requires its two SH2 domains to bind on adjacent pITIMs. Consequently, the binding of SHP-1, but not of SHIP1, increased with pITIM density on beads. When trying to increase Fc␥RIIB phosphorylation in B cells and mast cells, we found that concentrations of ligands optimal for Fc␥RIIB phosphorylation failed to induce SHP-1 recruitment. SHP-1 was, however, recruited by Fc␥RIIB when hyperphosphorylated following cell treatment with pervanadate. Our data suggest that Fc␥RIIB phosphorylation may not be sufficient in vivo to enable the recruitment of SHP-1 but that (pathological?) conditions that would hyperphosphorylate Fc␥RIIB might enable SHP-1 recruitment.Fc␥RIIB are single-chain low-affinity receptors for the Fc portion of IgG antibodies that bind multivalent immune complexes. They exist as two (Fc␥RIIB1 and B2 in humans) or three (Fc␥RIIB1, B1Ј, and B2 in mice) alternatively spliced products of the FcgR2b gene (1). All murine and human Fc␥RIIB isoforms were shown to negatively regulate cell activation induced by all receptors bearing intracytoplasmic immunoreceptor tyrosine-based activation motifs (ITAMs) 1 (2).Fc␥RIIB also negatively regulate cell proliferation induced by growth factor receptors with an intrinsic protein tyrosine kinase activity (3). Confirming these results, Fc␥RIIB-deficient mice were found: 1) to exhibit enhanced antibody responses (4); 2) to develop exaggerated IgE-(5) and IgG-dependent anaphylactic reactions (4); 3) to have an enhanced susceptibility to experimental murine models of IgG-dependent autoimmune diseases (6 -8); and 4) to exhibit enhanced antibody-dependent cell-mediated cytotoxic responses to the injection of therapeutic antibodies to tumor antigens (9). To inhibit cell activation, Fc␥RIIB need to be coaggregated with ITAM-bearing receptors by immune complexes or by any extracellular ligand capable of interacting with the two receptors simultaneously (10 -12). Coaggregation indeed enables Fc␥RIIB to be tyrosyl-phosphorylated by Lyn (13), a Src family protein tyrosine kinase provided by ITAM-bearing receptors. Fc␥RIIB isoforms contain a variable number of tyrosine residues in their intracytoplasmic domain, one of which proved to be critical (2,14). This tyrosine stands within a 13-amino acid seq...